Identifying how proteins and ligands interact is a cornerstone of modern medicine. Traditional drug discovery often struggles with the slow pace of structural analysis. Consequently, sequence-based deep learning models have emerged as a scalable alternative. These models predict interactions without needing complex 3D structures. However, many existing tools overlook the specific characteristics of the ligand itself. To bridge this gap, researchers developed LiBRe, a ligand-binding residue prediction model that integrates both protein and ligand data.

Advancing Virtual Screening with Ligand-Binding Residue Prediction

The LiBRe model represents a significant leap forward in computational pharmacology. By incorporating residue-level details and ligand-specific information, the model achieves superior accuracy. Moreover, it outperforms traditional sequence-based and even some structure-based baselines. This dual-aware approach ensures that the predicted binding sites are more biologically relevant. As a result, virtual screening becomes faster and more reliable for researchers worldwide.

Impact on Therapeutic Development

The practical applications of this model are vast. Pockets defined by LiBRe lead to stronger and more stable binding affinity predictions. This stability is crucial for designing effective drugs with fewer off-target effects. Furthermore, the source code is publicly available, encouraging collaborative innovation in the pharmaceutical industry. Such advancements are vital for addressing emerging health challenges in India and beyond.

Frequently Asked Questions

How does LiBRe differ from previous models?

Unlike older models that focus solely on protein sequences, LiBRe explicitly incorporates ligand information. This ligand-aware approach allows for more precise identification of residues involved in specific molecular recognition.

Why is sequence-based prediction important for drug discovery?

Sequence-based models are highly scalable and do not require 3D structural data, which is often unavailable for new proteins. This accelerates the initial phases of virtual screening.

What are the clinical implications of LiBRe for drug safety?

By accurately defining binding pockets, LiBRe helps researchers design drugs that fit precisely into their targets. This precision reduces the likelihood of binding to unintended proteins, potentially lowering side effects.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Always consult a qualified healthcare provider for personal medical needs. Refer to the latest local and national guidelines for clinical practice.

References

1. Kang K et al. LiBRe: A Ligand-Aware Sequence-Based Binding Residue Prediction Model for Virtual Screening. J Chem Inf Model. 2026 Mar 19. doi: 10.1021/acs.jcim.5c02883. PMID: 41856929.


2. Eurofins Discovery. Virtual Screening: Ligand-Based and Structure-Based Approaches for Drug Discovery. Available at: https://www.eurofinsdiscovery.com/solution/virtual-screening.


3. Pourmirzaei M et al. NeurIPS Zero-Shot Protein–Ligand Binding-Residue Prediction from Sequence and SMILES. 2026. Available at: https://neurips.cc/.